▼ Bevacizumab and ▼ cetuximab for colorectal cancer

Drug and Therapeutics Bulletin

Volumn 44, Issue 5, 2006, Pages 37-40

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT; BEVACIZUMAB; CETUXIMAB; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN; PLACEBO; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

ACNE; ARTERY OCCLUSION; ARTICLE; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; COLORECTAL CANCER; COST EFFECTIVENESS ANALYSIS; DIGESTIVE SYSTEM PERFORATION; DRUG CONTRAINDICATION; DRUG COST; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG ERUPTION; DRUG HYPERSENSITIVITY; DRUG RECEPTOR BINDING; DRUG SAFETY; EPISTAXIS; HEART INFARCTION; HUMAN; HYPERTENSION; METASTASIS; PRIMARY HEALTH CARE; PROGNOSIS; PROTEINURIA; QUALITY OF LIFE; RANDOMIZATION; SKIN BLEEDING; THROMBOSIS; TRANSIENT ISCHEMIC ATTACK; COLORECTAL TUMOR;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; COLORECTAL NEOPLASMS; HUMANS;

EID: 33646768571     PISSN: 00126543     EISSN: None     Source Type: Journal    
DOI: 10.1136/dtb.2006.44537     Document Type: Article

References (29)

1. Cancer Research UK, September 2005. Cancer Stats Mortality - UK [online]. Available: http://info.cancerresearchuk.org/cancerstats/mortality/cancerdeaths/ ?a=5441 [Accessed 19 April 2006].
2. Colorectal Cancer Collaborative Group. Palliative chemotherapy for advanced colorectal cancer: systematic review and meta-analysis. BMJ 2000;321:531-5.
3. Goldberg RM et al. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 2OO4;22:23-30.
4. Tournigand C et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol 2004;22:229-37.
5. Weitz J et al. Colorectal cancer. Lancet 2005; 365: 153-65.
6. de Gramont A et al. Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: a French intergroup study. J Clin Oncol 1997; 15: 808-15.
7. Maughan TS et al. Comparison of survival, palliation, and quality of life with three chemotherapy regimens in metastatic colorectal cancer: a multicentre randomised trial. Lancet 2002; 359: 1555-63.
8. Chemotherapy for metastatic colorectal cancer. DTB 2002;40:49-52.
9. National Institute for Health and Clinical Excellence, August 2005. irinotecan, oxaliplatin and raltitrexed for the treatment of advanced colorectal cancer [online]. Available: http://www.nice.org.uk/pdf/TA93Guidance.pdf [Accessed 19 April 2006].
10. Van Cutsem E et al. Oral capecitabine vs intravenous 5-fluorouracil and leucovorin: integrated efficacy data and novel analyses from two large, randomised, phase III trials. Br J Cancer 2004;90:1190-7.
11. Nogué M et al. Randomised study of tegafur and oral leucovorin versus intravenous 5-fluorouracil and leucovorin in patients with advanced colorectal cancer. Eur J Cancer 2005; 41: 2241-9.
12. Ellis LM et al. Vascular endothelial growth factor in human colon cancer: biology and therapeutic implications, Oncologist 2000; 5 (suppl 1): 11-5.
13. Takahashi Y et al. Expression of vascular endothelial growth factor and its receptor, KDR, correlates with vascularity, metastasis, and proliferation of human colon cancer. Cancer Res 1995; 55: 3964-8.
14. Avastin 25mg/mL concentrate for solution for infusion, Summary of product characteristics, UK. Roche Registration Limited, December 2005.
15. Committee for Medicinal Products for Human Use. European Public Assessment Report (EPAR), Avastin. London: European Agency for the Evaluation of Medicinal Products, 2005.
16. Hurwitz H et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2OO4;350:2335-42.
17. Kabbinavar F et al. Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol 2003;21:60-5.
18. Kabbinavar FF et al. Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial. J Clin Oncol 2005; 23: 3697-705.
19. Giantonio BJ et al. High-dose bevacizumab improves survival when combined with FOLFOX4 in previously treated advanced colorectal cancer: results from the Eastern Cooperative Oncology Group (ECOG) study E3200. J Clin Oncol 2005; 23 (June 1 suppl): 2 [abstract].
20. Scottish Medicines Consortium, January 2006. Press statement. The Soottish Medicines Consortium issues advice on bevacizumab (Avastin) for use within NHS Scotland [online]. Available: http://www.scottishmedicines.org.uk/press/detail.asp?id=833 [Accessed 19 April 2006].
21. Cunningham D et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory colorectal cancer. N Engl J Med 2004;351:337-45.
22. Woodburn JR. The epidermal growth factor receptor and its inhibition in cancer therapy. Pharmacol Ther 1999;82:241-50.
23. Saltz LB et al. Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol 2004;22:1201-8.
24. Committee for Medicinal Products for Human Use. European Public Assessment Report (EPAR). Erbitux. London: European Agency for the Evaluation of Medicinal Products, 2004.
25. Erbitux 2mg/mL solution for infusion. Summary of product characteristics, Germany. Merck KGaA, September 2005.
26. Chung KY et al. Cetuximab shows activity in colorectal cancer patients with tumours that do not express the epidermal growth factor receptor by immunohistochemistry. J Clin Oncol 2005;23:1803-10,
27. Segaert S et al. The management of skin reactions in cancer patients receiving epidermal growth factor receptor targeted therapies. J Dtsch Dermatol Ges 2005;3:599-606.
28. Scottish Medicines Consortium, March 2005. Press statement The Scottish Medicines Consortium issues advice on cetuximab (Erbitux) for colorectal cancer [online]. Available: http://www.scottishmedicines.org.uk/press/detail.asp?id=599 [Accessed 19 April 2006].
29. All Wales Medicines Strategy Group. Draft minutes held Thursday 2nd, March 2006 [online]. Available: http://www.wales.nhs.uk/sites3/ docopen.cfm?orgid=371&ID=54720&1D06E62C-97F8-407D- B838BB8C4C57F688 [Accessed 19 April 2006].